A First-In-Human study of HS-10383, a Selective P2X3 Receptor Antagonist for the treatment of Refractory or Unexplained Chronic Cough, in Healthy Chinese Subjects

被引：0
|
作者：
Li, Qian [1 ,2 ]
Chen, Ke-Guang [1 ,2 ]
Zhang, Ye-Hui [1 ,2 ]
Zhou, Hai-Yan [1 ,2 ]
Ye, Pan-Pan [1 ,2 ]
Song, Lin-Lin [1 ,2 ]
Zhao, Fu-Rong [1 ,2 ]
Shi, Jin-Yi [1 ,2 ]
Wu, Qiong [3 ]
Yu, Xiang-Qing [3 ]
Pan, Chao [3 ]
Yuan, Dong [3 ]
Xu, Miao [3 ]
Xing, Aiping [3 ]
Yang, Xin-Mei [1 ,2 ]
Zhao, Wei [1 ,2 ,4 ]
机构：
[1] Shandong First Med Univ, Dept Clin Pharm, Affiliated Hosp 1, Jinan, Peoples R China
[2] Shandong Prov Qianfoshan Hosp, Shandong Engn & Technol Res Ctr Pediat Drug Dev, Shandong Med & Hlth Key Lab Clin Pharm, Jinan, Peoples R China
[3] Jiangsu Hansoh Pharmaceut Grp Co Ltd, Dept Clin Pharm, Lianyungang, Peoples R China
[4] Shandong Univ, Sch Pharmaceut Sci, Minist Educ,Dept Clin Pharm, Key Lab Chem Biol,Cheeloo Coll Med, Jinan, Peoples R China
来源：
RESPIROLOGY | 2023年 / 28卷
关键词：
D O I：
暂无
中图分类号：
R56 [呼吸系及胸部疾病];
学科分类号：
摘要：
AO13-6
引用
收藏
页码：60 / 61
页数：2
相关论文
共 50 条
  • [31] BLU-5937 a Highly Selective P2X3 Homotrimeric Receptor Antagonist with Improved Taste Safety Profile in Healthy Subjects
    Garceau, D.
    Chauret, N.
    Harvey, L.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2019, 199
  • [32] A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Phase 2b Trial of P2X3 Receptor Antagonist Sivopixant for Refractory or Unexplained Chronic Cough
    McGarvey, Lorcan
    Smith, Jaclyn A.
    Morice, Alyn
    Birring, Surinder S.
    Chung, Kian Fan
    Dicpinigaitis, Peter, V
    Niimi, Akio
    Benninger, Michael S.
    Sher, Mandel
    Matsunaga, Yuko
    Miyazaki, Sayaka
    Machida, Mitsuaki
    Ishihara, Hiroyuki
    Mahmood, Adnan
    Gomez, Juan-Carlos
    LUNG, 2023, 201 (01) : 25 - 35
  • [33] A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Phase 2b Trial of P2X3 Receptor Antagonist Sivopixant for Refractory or Unexplained Chronic Cough
    Lorcan McGarvey
    Jaclyn A. Smith
    Alyn Morice
    Surinder S. Birring
    Kian Fan Chung
    Peter V. Dicpinigaitis
    Akio Niimi
    Michael S. Benninger
    Mandel Sher
    Yuko Matsunaga
    Sayaka Miyazaki
    Mitsuaki Machida
    Hiroyuki Ishihara
    Adnan Mahmood
    Juan-Carlos Gomez
    Lung, 2023, 201 : 25 - 35
  • [34] Discovery of MK-2548: A P2X3 receptor antagonist for the treatment of chronic pain
    Paone, Daniel
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2016, 251
  • [35] Efficacy and safety of gefapixant, a P2X3 receptor antagonist, in refractory chronic cough and unexplained chronic cough (COUGH-1 and COUGH-2): results from two double-blind, randomised, parallel-group, placebo-controlled, phase 3 trials
    McGarvey, Lorcan P.
    Birring, Surinder S.
    Morice, Alyn H.
    Dicpinigaitis, Peter V.
    Pavord, Ian D.
    Schelfhout, Jonathan
    Nguyen, Allison Martin
    Li, Qing
    Tzontcheva, Anjela
    Iskold, Beata
    Green, Stuart A.
    La Rosa, Carmen
    Muccino, David R.
    Smith, Jaclyn A.
    LANCET, 2022, 399 (10328): : 909 - 923
  • [36] Eliapixant is a selective P2X3 receptor antagonist for the treatment of disorders associated with hypersensitive nerve fibers
    Adam J. Davenport
    Ioana Neagoe
    Nico Bräuer
    Markus Koch
    Andrea Rotgeri
    Jens Nagel
    Alexis Laux-Biehlmann
    Frederic Machet
    Anne-Marie Coelho
    Susan Boyce
    Nikisha Carty
    Mark J. Gemkow
    Stephen D. Hess
    Thomas M. Zollner
    Oliver M. Fischer
    Scientific Reports, 11
  • [37] Eliapixant is a selective P2X3 receptor antagonist for the treatment of disorders associated with hypersensitive nerve fibers
    Davenport, Adam J.
    Neagoe, Ioana
    Braeuer, Nico
    Koch, Markus
    Rotgeri, Andrea
    Nagel, Jens
    Laux-Biehlmann, Alexis
    Machet, Frederic
    Coelho, Anne-Marie
    Boyce, Susan
    Carty, Nikisha
    Gemkow, Mark J.
    Hess, Stephen D.
    Zollner, Thomas M.
    Fischer, Oliver M.
    SCIENTIFIC REPORTS, 2021, 11 (01)
  • [38] Structure -: Activity relationship studies of spinorphin as a potent and selective human P2X3 receptor antagonist
    Jung, Kwan-Young
    Moon, Hyoun Duk
    Lee, Ga Eun
    Lim, Hyun-Ho
    Park, Chul-Seung
    Kim, Yong-Chu
    JOURNAL OF MEDICINAL CHEMISTRY, 2007, 50 (18) : 4543 - 4547
  • [39] Model-based Dose Selection for Phase 3 Trials of the Selective P2X3 Antagonist Camlipixant in efractory Chronic Cough
    Chauret, N.
    Garin, M.
    Harvey, L.
    Gahir, S.
    Yang, T.
    Garceau, D.
    Bonuccelli, C. M.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2023, 207
  • [40] Characterization of chronic cough patients participating in a phase 2b clinical trial of gefapixant, a P2X3 receptor antagonist
    McGarvey, Lorcan
    Smith, Jaclyn
    Birring, Surinder
    Morice, Alyn
    Sher, Mandel
    Wu, Wen-Chi
    Muccino, David
    EUROPEAN RESPIRATORY JOURNAL, 2019, 54
12345